[G03XB02, ulipristal, The metabolism of Ulipristal can be increased when combined with Sarilumab.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sarilumab.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Sarilumab.]
[L04AA27, fingolimod, Sarilumab may increase the immunosuppressive activities of Fingolimod.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Sarilumab.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Sarilumab.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be increased when combined with Sarilumab.]
[L01CB02, teniposide, The metabolism of Teniposide can be increased when combined with Sarilumab.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Sarilumab.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Sarilumab.]
[R03DA04, theophylline, The metabolism of Theophylline can be increased when combined with Sarilumab.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Eribulin is combined with Sarilumab.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be increased when combined with Sarilumab.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Sarilumab.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Sarilumab.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Sarilumab.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Sarilumab.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Sarilumab.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Sarilumab is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Sarilumab.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Sarilumab.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Belimumab is combined with Sarilumab.]
[L01FX04, ipilimumab, The risk or severity of adverse effects can be increased when Ipilimumab is combined with Sarilumab.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be increased when combined with Sarilumab.]
[A10BH05, linagliptin, The metabolism of Linagliptin can be increased when combined with Sarilumab.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Sarilumab.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Belatacept is combined with Sarilumab.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be increased when combined with Sarilumab.]
[L01CA02, vincristine, The metabolism of Vincristine can be increased when combined with Sarilumab.]
[L01CA03, vindesine, The metabolism of Vindesine can be increased when combined with Sarilumab.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Sarilumab.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Sarilumab.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be increased when combined with Sarilumab.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be increased when combined with Sarilumab.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be increased when combined with Sarilumab.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be increased when combined with Sarilumab.]
[N05AE04, ziprasidone, The metabolism of Ziprasidone can be increased when combined with Sarilumab.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be increased when combined with Sarilumab.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sarilumab.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be increased when combined with Sarilumab.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sarilumab.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Sarilumab.]
[L01EK01, axitinib, The metabolism of Axitinib can be increased when combined with Sarilumab.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Sarilumab is combined with Prednylidene.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Sarilumab.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Sarilumab.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Sarilumab.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Sarilumab.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sarilumab.]
[L01FD02, pertuzumab, The risk or severity of adverse effects can be increased when Pertuzumab is combined with Sarilumab.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Carfilzomib is combined with Sarilumab.]
[L02BB04, enzalutamide, The serum concentration of Enzalutamide can be increased when it is combined with Sarilumab.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be increased when combined with Sarilumab.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Sarilumab.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Abetimus is combined with Sarilumab.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Aldosterone is combined with Sarilumab.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be increased when combined with Sarilumab.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Bendamustine is combined with Sarilumab.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Sarilumab.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Sarilumab.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be increased when combined with Sarilumab.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Sarilumab.]
[J06BC02, raxibacumab, The risk or severity of adverse effects can be increased when Raxibacumab is combined with Sarilumab.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be increased when combined with Sarilumab.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Sarilumab.]
[L04AA18, everolimus, The metabolism of Everolimus can be increased when combined with Sarilumab.]
[L01EC02, dabrafenib, The metabolism of Dabrafenib can be increased when combined with Sarilumab.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be increased when combined with Sarilumab.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Sarilumab.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be increased when combined with Sarilumab.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be increased when combined with Sarilumab.]
[L04AA32, apremilast, The therapeutic efficacy of Apremilast can be decreased when used in combination with Sarilumab.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Sarilumab.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Siltuximab is combined with Sarilumab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be increased when combined with Sarilumab.]
[L01FG02, ramucirumab, The risk or severity of adverse effects can be increased when Ramucirumab is combined with Sarilumab.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be increased when combined with Sarilumab.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Vedolizumab is combined with Sarilumab.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Sarilumab.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Belinostat is combined with Sarilumab.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be increased when combined with Sarilumab.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Peginterferon beta-1a is combined with Sarilumab.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be increased when combined with Sarilumab.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Sarilumab.]
[L01FF02, pembrolizumab, The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Sarilumab.]
[A10BJ05, dulaglutide, The risk or severity of adverse effects can be increased when Dulaglutide is combined with Sarilumab.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Decitabine is combined with Sarilumab.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Pirfenidone is combined with Sarilumab.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be increased when combined with Sarilumab.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Sarilumab.]
[L01XK01, olaparib, The metabolism of Olaparib can be increased when combined with Sarilumab.]
[L01FF01, nivolumab, The risk or severity of adverse effects can be increased when Nivolumab is combined with Sarilumab.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Sarilumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be increased when combined with Sarilumab.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be increased when combined with Sarilumab.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Sarilumab.]
[C10AX14, alirocumab, The risk or severity of adverse effects can be increased when Alirocumab is combined with Sarilumab.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be increased when combined with Sarilumab.]
[C10AX13, evolocumab, The risk or severity of adverse effects can be increased when Evolocumab is combined with Sarilumab.]
[V03AB37, idarucizumab, The risk or severity of adverse effects can be increased when Idarucizumab is combined with Sarilumab.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be increased when combined with Sarilumab.]
[A16AB13, asfotase alfa, The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Sarilumab.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Mepolizumab is combined with Sarilumab.]
[J02AC05, isavuconazole, The metabolism of Isavuconazole can be increased when combined with Sarilumab.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be increased when combined with Sarilumab.]
[J05AF13, tenofovir alafenamide, The metabolism of Tenofovir alafenamide can be increased when combined with Sarilumab.]
[L01FC01, daratumumab, The risk or severity of adverse effects can be increased when Daratumumab is combined with Sarilumab.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be increased when combined with Sarilumab.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be increased when combined with Sarilumab.]
[L01FE03, necitumumab, The risk or severity of adverse effects can be increased when Necitumumab is combined with Sarilumab.]
[L01FX08, elotuzumab, The risk or severity of adverse effects can be increased when Elotuzumab is combined with Sarilumab.]
[L01ED03, alectinib, The metabolism of Alectinib can be increased when combined with Sarilumab.]
[J06BB02, tetanus immune globulin, The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Sarilumab.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Sarilumab.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Ixekizumab is combined with Sarilumab.]
[R03DX08, reslizumab, The risk or severity of adverse effects can be increased when Reslizumab is combined with Sarilumab.]
[J06BC04, obiltoxaximab, The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Sarilumab.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be increased when combined with Sarilumab.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Sarilumab.]
[L01FF05, atezolizumab, The risk or severity of adverse effects can be increased when Atezolizumab is combined with Sarilumab.]
[L01AB01, busulfan, The metabolism of Busulfan can be increased when combined with Sarilumab.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Sarilumab.]
[J06BC03, bezlotoxumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Bezlotoxumab.]
[L01FX10, olaratumab, The risk or severity of adverse effects can be increased when Olaratumab is combined with Sarilumab.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be increased when combined with Sarilumab.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Brodalumab.]
[L01EF02, ribociclib, The metabolism of Ribociclib can be increased when combined with Sarilumab.]
[L01FF04, avelumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Avelumab.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Ocrelizumab.]
[D11AH05, dupilumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Dupilumab.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Sarilumab.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Sarilumab.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Sarilumab.]
[L01EX10, midostaurin, The metabolism of Midostaurin can be increased when combined with Sarilumab.]
[L01FF03, durvalumab, The risk or severity of adverse effects can be increased when Durvalumab is combined with Sarilumab.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be increased when combined with Sarilumab.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Sarilumab.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Capecitabine is combined with Sarilumab.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be increased when combined with Sarilumab.]
[L01EH02, neratinib, The metabolism of Neratinib can be increased when combined with Sarilumab.]
[J06BD01, palivizumab, The risk or severity of adverse effects can be increased when Palivizumab is combined with Sarilumab.]
[L01FB01, inotuzumab ozogamicin, The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sarilumab.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Vorinostat is combined with Sarilumab.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be increased when combined with Sarilumab.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be increased when combined with Sarilumab.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Sarilumab.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Sarilumab.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Budesonide is combined with Sarilumab.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be increased when combined with Sarilumab.]
[R03DX10, benralizumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Benralizumab.]
[B02BX06, emicizumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Emicizumab.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be increased when combined with Sarilumab.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Sarilumab.]
[J05AX23, ibalizumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Ibalizumab.]
[M05BX05, burosumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Burosumab.]
[N02CD01, erenumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Erenumab.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Sarilumab is combined with Baricitinib.]
[L01XX62, ivosidenib, The metabolism of Ivosidenib can be increased when combined with Sarilumab.]
[L04AC17, tildrakizumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Tildrakizumab.]
[L01FX09, mogamulizumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Mogamulizumab.]
[B06AC05, lanadelumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Lanadelumab.]
[N02CD03, fremanezumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Fremanezumab.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be increased when combined with Sarilumab.]
[L01FF06, cemiplimab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Cemiplimab.]
[N02CD02, galcanezumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Galcanezumab.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be increased when combined with Sarilumab.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Sarilumab.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be increased when combined with Sarilumab.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Ravulizumab is combined with Sarilumab.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Sarilumab.]
[B01AX07, caplacizumab, The risk or severity of adverse effects can be increased when Caplacizumab is combined with Sarilumab.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Sarilumab.]
[L04AA42, siponimod, The metabolism of Siponimod can be increased when combined with Sarilumab.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be increased when combined with Sarilumab.]
[M05BX06, romosozumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Romosozumab.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Sarilumab is combined with Cloprednol.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Sarilumab.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Sarilumab is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Risankizumab.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be increased when combined with Sarilumab.]
[L01FX14, polatuzumab vedotin, The risk or severity of adverse effects can be increased when Sarilumab is combined with Polatuzumab vedotin.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be increased when combined with Sarilumab.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Sarilumab is combined with Upadacitinib.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be increased when combined with Sarilumab.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be increased when combined with Sarilumab.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be increased when combined with Sarilumab.]
[S01LA06, brolucizumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Brolucizumab.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be increased when combined with Sarilumab.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Sarilumab is combined with Deflazacort.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Sarilumab.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Sarilumab.]
[L01FD04, trastuzumab deruxtecan, The risk or severity of adverse effects can be increased when Sarilumab is combined with Trastuzumab deruxtecan.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Sarilumab is combined with Diroximel fumarate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be increased when combined with Sarilumab.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Sarilumab.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Sarilumab.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Sarilumab.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Sarilumab.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be increased when combined with Sarilumab.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Teprotumumab is combined with Sarilumab.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be decreased when it is combined with Sarilumab.]
[L01FC02, isatuximab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Isatuximab.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Sarilumab.]
[N02CD05, eptinezumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Eptinezumab.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Sarilumab is combined with Ozanimod.]
[G03DB08, dienogest, The metabolism of Dienogest can be increased when combined with Sarilumab.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Sarilumab.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be increased when combined with Sarilumab.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Sarilumab.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Sarilumab.]
[L01FX17, sacituzumab govitecan, The risk or severity of adverse effects can be increased when Sarilumab is combined with Sacituzumab govitecan.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Sarilumab.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Fluprednidene is combined with Sarilumab.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Sarilumab.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Sarilumab is combined with Inebilizumab.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Stepronin is combined with Sarilumab.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Sarilumab.]
[R06AX22, ebastine, The metabolism of Ebastine can be increased when combined with Sarilumab.]
[L01FX12, tafasitamab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Tafasitamab.]
[L01FX15, belantamab mafodotin, The risk or severity of adverse effects can be increased when Sarilumab is combined with Belantamab mafodotin.]
[L04AC19, satralizumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Satralizumab.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be decreased when it is combined with Sarilumab.]
[G03CA06, chlorotrianisene, Chlorotrianisene may increase the thrombogenic activities of Sarilumab.]
[N05AA01, chlorpromazine, The metabolism of Chlorpromazine can be increased when combined with Sarilumab.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Sarilumab.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Sarilumab.]
[J06BD04, ansuvimab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Ansuvimab.]
[L01FD06, margetuximab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Margetuximab.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Voclosporin is combined with Sarilumab.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Sarilumab.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Sarilumab.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Sarilumab is combined with Ponesimod.]
[S01LA08, bevacizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sarilumab.]
[L01EK03, tivozanib, The metabolism of Tivozanib can be increased when combined with Sarilumab.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Sarilumab.]
[L01FF07, dostarlimab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Dostarlimab.]
[L01FX22, loncastuximab tesirine, The risk or severity of adverse effects can be increased when Sarilumab is combined with Loncastuximab tesirine.]
[L01FX18, amivantamab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Amivantamab.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be increased when combined with Sarilumab.]
[J06BD05, sotrovimab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Sotrovimab.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Sarilumab.]
[N06DX03, aducanumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Aducanumab.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Sarilumab is combined with Pegcetacoplan.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Sarilumab.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Sarilumab is combined with Belumosudil.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Anifrolumab.]
[L01FX23, tisotumab vedotin, The risk or severity of adverse effects can be increased when Sarilumab is combined with Tisotumab vedotin.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Sarilumab.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Sarilumab is combined with Ropeginterferon alfa-2b.]
[R03DX11, tezepelumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Tezepelumab.]
[D11AH07, tralokinumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Tralokinumab.]
[L04AA55, sutimlimab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Sutimlimab.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be increased when combined with Sarilumab.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be increased when combined with Sarilumab.]
[S01EA04, clonidine, The metabolism of Clonidine can be increased when combined with Sarilumab.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Sarilumab is combined with Deucravacitinib.]
[L01FX20, tremelimumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Tremelimumab.]
[L04AA57, ublituximab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Ublituximab.]
[L01FE02, panitumumab, The risk or severity of adverse effects can be increased when Panitumumab is combined with Sarilumab.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Bimekizumab.]
[J06BB04, hepatitis B immune globulin, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Sarilumab.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Sarilumab.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Sarilumab is combined with Leflunomide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Nelarabine is combined with Sarilumab.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Ciclesonide is combined with Sarilumab.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Sarilumab.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Meprednisone is combined with Sarilumab.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Sarilumab.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be increased when combined with Sarilumab.]
[S01XA18, cyclosporine, Sarilumab may increase the immunosuppressive activities of Cyclosporine.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be increased when combined with Sarilumab.]
[C03XA02, conivaptan, The metabolism of Conivaptan can be increased when combined with Sarilumab.]
[R03DX05, omalizumab, The risk or severity of adverse effects can be increased when Omalizumab is combined with Sarilumab.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Sarilumab.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Sarilumab.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Sarilumab.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Sarilumab.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Sarilumab.]
[L01FE01, cetuximab, The risk or severity of adverse effects can be increased when Cetuximab is combined with Sarilumab.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Sarilumab.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sarilumab.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Sarilumab.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Sarilumab.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Dexamethasone is combined with Sarilumab.]
[L04AB04, adalimumab, The risk or severity of infection can be increased when Adalimumab is combined with Sarilumab.]
[G03CC02, dienestrol, Dienestrol may increase the thrombogenic activities of Sarilumab.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be increased when combined with Sarilumab.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be decreased when it is combined with Sarilumab.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Pirarubicin is combined with Sarilumab.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be increased when combined with Sarilumab.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Sarilumab.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be increased when combined with Sarilumab.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may increase the thrombogenic activities of Sarilumab.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sarilumab.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be increased when combined with Sarilumab.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be increased when combined with Sarilumab.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Sarilumab.]
[J05AE08, atazanavir, The metabolism of Atazanavir can be increased when combined with Sarilumab.]
[G03CA09, promestriene, Promestriene may increase the thrombogenic activities of Sarilumab.]
[A03FA02, cisapride, The metabolism of Cisapride can be increased when combined with Sarilumab.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be increased when combined with Sarilumab.]
[J06BB01, Rho(D) immune globulin, The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Sarilumab.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Natalizumab.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Sarilumab.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be increased when combined with Sarilumab.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be increased when combined with Sarilumab.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be increased when combined with Sarilumab.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be increased when combined with Sarilumab.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be increased when combined with Sarilumab.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Corticotropin is combined with Sarilumab.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Sarilumab.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be increased when combined with Sarilumab.]
[G03CX01, tibolone, Tibolone may increase the thrombogenic activities of Sarilumab.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Sarilumab.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Sarilumab is combined with Trofosfamide.]
[J06BB03, varicella-zoster immune globulin, The risk or severity of adverse effects can be increased when Human varicella-zoster immune globulin is combined with Sarilumab.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be increased when combined with Sarilumab.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Sarilumab.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Sarilumab.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Sarilumab.]
[N02CA02, ergotamine, The metabolism of Ergotamine can be increased when combined with Sarilumab.]
[G03CA03, estradiol, The metabolism of Estradiol can be increased when combined with Sarilumab.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Sarilumab.]
[G03CC06, estriol, Estriol may increase the thrombogenic activities of Sarilumab.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may increase the thrombogenic activities of Sarilumab.]
[G03CC04, estrone, Estrone may increase the thrombogenic activities of Sarilumab.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Sarilumab.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Sarilumab is combined with Fluticasone.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be increased when combined with Sarilumab.]
[L01CB01, etoposide, The metabolism of Etoposide can be increased when combined with Sarilumab.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Sarilumab.]
[R06AX11, astemizole, The metabolism of Astemizole can be increased when combined with Sarilumab.]
[R06AX12, terfenadine, The metabolism of Terfenadine can be increased when combined with Sarilumab.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Sarilumab.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sarilumab.]
[P02CA03, albendazole, The metabolism of Albendazole can be increased when combined with Sarilumab.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Sarilumab.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Sarilumab.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Sarilumab.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Sarilumab.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Sarilumab.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Fluocinonide is combined with Sarilumab.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Fluocortolone is combined with Sarilumab.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Sarilumab.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Sarilumab.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Sarilumab.]
[N05CF04, eszopiclone, The serum concentration of Eszopiclone can be decreased when it is combined with Sarilumab.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be increased when combined with Sarilumab.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be increased when combined with Sarilumab.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Sarilumab.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be increased when combined with Sarilumab.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be increased when combined with Sarilumab.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be increased when combined with Sarilumab.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Sarilumab.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be increased when combined with Sarilumab.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be increased when combined with Sarilumab.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Sarilumab.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Sarilumab.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Sarilumab.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Idarubicin is combined with Sarilumab.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be increased when combined with Sarilumab.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be increased when combined with Sarilumab.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Tixocortol is combined with Sarilumab.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Sarilumab.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Sarilumab.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Sarilumab.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sarilumab.]
[N06AX17, milnacipran, The metabolism of Milnacipran can be increased when combined with Sarilumab.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Sarilumab.]
[S01LA04, ranibizumab, The risk or severity of adverse effects can be increased when Ranibizumab is combined with Sarilumab.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Sarilumab.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sarilumab.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Tocilizumab is combined with Sarilumab.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Abatacept is combined with Sarilumab.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be increased when combined with Sarilumab.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Sarilumab.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be increased when combined with Sarilumab.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Sarilumab.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Lomustine is combined with Sarilumab.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Sarilumab.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Sarilumab.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be increased when combined with Sarilumab.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Pralatrexate is combined with Sarilumab.]
[L01EA03, nilotinib, The metabolism of Nilotinib can be increased when combined with Sarilumab.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Sarilumab.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Sarilumab.]
[N02AB02, meperidine, The metabolism of Meperidine can be increased when combined with Sarilumab.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Methimazole is combined with Sarilumab.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Sarilumab.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be increased when combined with Sarilumab.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be increased when combined with Sarilumab.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Sarilumab.]
[N02CA04, methysergide, The metabolism of Methysergide can be increased when combined with Sarilumab.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Sarilumab.]
[G03XB01, mifepristone, The metabolism of Mifepristone can be increased when combined with Sarilumab.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Sarilumab.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sarilumab.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be increased when combined with Sarilumab.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Sarilumab.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Ofatumumab is combined with Sarilumab.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be increased when combined with Sarilumab.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Sarilumab.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be increased when combined with Sarilumab.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sarilumab.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Sarilumab.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be increased when combined with Sarilumab.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Sarilumab.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Sarilumab.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be increased when combined with Sarilumab.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Sarilumab.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be increased when combined with Sarilumab.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Rilonacept is combined with Sarilumab.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Sarilumab.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Paramethasone is combined with Sarilumab.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Sarilumab.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Sarilumab.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Sarilumab.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Sarilumab.]
[L01FX01, edrecolomab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Edrecolomab.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Sarilumab.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be increased when combined with Sarilumab.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Golimumab is combined with Sarilumab.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be increased when combined with Sarilumab.]
[N05AG02, pimozide, The metabolism of Pimozide can be increased when combined with Sarilumab.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Sarilumab.]
[B01AC13, abciximab, The risk or severity of adverse effects can be increased when Abciximab is combined with Sarilumab.]
[L04AC05, ustekinumab, The risk or severity of adverse effects can be increased when Ustekinumab is combined with Sarilumab.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Canakinumab is combined with Sarilumab.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Sarilumab.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Sarilumab.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Sarilumab.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be increased when combined with Sarilumab.]
[G03DA04, progesterone, The metabolism of Progesterone can be increased when combined with Sarilumab.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be increased when combined with Sarilumab.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Sarilumab.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be increased when combined with Sarilumab.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Sarilumab.]
[C01BA01, quinidine, The metabolism of Quinidine can be increased when combined with Sarilumab.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Sarilumab.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Sarilumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Sarilumab.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be increased when combined with Sarilumab.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Sarilumab.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be increased when combined with Sarilumab.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Sarilumab is combined with Hydrocortisone butyrate.]
